GLP-1 agonists
DEGLP-1-Agonisten
GLP-1 receptor agonists copy a gut hormone called glucagon-like peptide-1. Examples are liraglutide, semaglutide, and dulaglutide. They prompt your pancreas to release insulin when blood sugar is high. They also hold back glucagon, slow how fast your stomach empties, and curb appetite. They are approved for type 2 diabetes and obesity. Big trials show they cut cardiovascular events. Semaglutide is now also approved to slow kidney disease in type 2 diabetes with chronic kidney disease (FDA, January 2025, the FLOW trial). And it is being studied to ease heart-failure symptoms in HFpEF. The longevity-relevant upsides are weight loss, better blood sugar, and possibly calmer brain inflammation. Taking them purely for healthspan in metabolically healthy adults is still experimental. There is also a supply story. On 21 February 2025 the FDA declared the US semaglutide shortage over. That ended the 503A/503B compounding window for it. Tirzepatide compounding was similarly restricted after a 2024 preliminary-injunction denial. And on 30 April 2026 the FDA proposed a permanent 503B bulks exclusion for semaglutide, tirzepatide, and liraglutide.
Last reviewed:
This definition is educational and is not medical advice, a diagnosis, or treatment. Talk to a doctor about any health decisions. Read our full medical disclaimer